Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
Christos I Sinapis1,*, John G Routsias2,*, Angelos I Sinapis1,*, Dimitrios I Sinapis1,*, George D Agrogiannis3, Alkistis Pantopoulou1, Stamatis E Theocharis4, Stefanos Baltatzis5, Efstratios Patsouris3, Despoina Perrea11Laboratory for Experimental Surgery and Surgical Research 'N.S.Chris...
Guardado en:
Autores principales: | Sinapis C, Routsias JG, Sinapis A, Sinapis D, Agrogiannis G, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E, Perrea DN |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/af53d795422f483f931ce5320837b88f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
por: Nicola G Ghazi, et al.
Publicado: (2010) -
The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration
por: Ehud Rechtman, et al.
Publicado: (2011) -
Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin®) for AMD followed by controlateral sympathetic ophthalmia
por: Dimitrios Brouzas, et al.
Publicado: (2009) -
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Dimitrios Brouzas, et al.
Publicado: (2009) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008)